Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine

Linda Steinbaugh, Jerzy P SzaflarskiDepartment of Neurology and Cincinnati Epilepsy Center, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USAAbstract: Idiopathic generalized epilepsies are frequently encountered by neurologists, and providing an accurate diagnosis and effective...

Full description

Saved in:
Bibliographic Details
Main Authors: Linda Steinbaugh (Author), Jerzy P Szaflarski (Author)
Format: Book
Published: Dove Medical Press, 2010-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f5db22d7f0c34b88ad05d145de50f62f
042 |a dc 
100 1 0 |a Linda Steinbaugh  |e author 
700 1 0 |a Jerzy P Szaflarski  |e author 
245 0 0 |a Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine 
260 |b Dove Medical Press,   |c 2010-11-01T00:00:00Z. 
500 |a 1177-8881 
520 |a Linda Steinbaugh, Jerzy P SzaflarskiDepartment of Neurology and Cincinnati Epilepsy Center, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USAAbstract: Idiopathic generalized epilepsies are frequently encountered by neurologists, and providing an accurate diagnosis and effective treatment(s) are the necessary components of successful patient care. With the introduction of new antiepileptic medications, physicians are better equipped for this goal. The immediate-release formulation of lamotrigine (LTG-IR) has been approved for primary generalized tonic-clonic seizures since 2006. The extended-release formulation of lamotrigine (LTG-XR) was approved for adjunctive therapy in patients with primary generalized tonic-clonic seizures in 2010. Although its exact mechanism of action is not yet fully elucidated, studies have demonstrated multiple possible pathways. Although both the LTG-IR and LTG-XR formulations have similar side effects and are generally well tolerated, LTG-XR may be preferable for its ease of use, which may increase patient compliance and decrease fluctuations in serum drug levels. The ease of conversion between the formulations also makes lamotrigine an attractive treatment option for patients with primary generalized tonic-clonic seizures. LTG-IR has demonstrated efficacy in treatment-resistant idiopathic generalized epilepsies in both adults and children. Although there are still some questions regarding all possible applications of LTG-XR, as further research is being done, it is clear that LTG-XR may hold some advantages when compared with other anticonvulsants.Keywords: lamotrigine, GTC, IGE, generalized seizures, treatment 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Design, Development and Therapy, Vol 2010, Iss default, Pp 337-342 (2010) 
787 0 |n http://www.dovepress.com/adjunctive-therapy-for-the-treatment-of-primary-generalized-tonic-clon-a5678 
787 0 |n https://doaj.org/toc/1177-8881 
856 4 1 |u https://doaj.org/article/f5db22d7f0c34b88ad05d145de50f62f  |z Connect to this object online.